Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

However, no difference was found because VSL#3 was still better in obtaining remission at the end of 8 weeks than placebo, and the result did not reach statistical significance (28 (42.4%) vs. 20 (29%), respectively; PP P =0.067; ITT P =0.110).

also in 111,027 other papers